Posted on December 24, 2020
Dr. Kira Sheinerman, Ph.D. (Bronfman parent ’17), is a Managing Director of Investment Banking at H.C. Wainwright. Dr. Sheinerman is also the co-founder and director of DiamiR Biosciences, a privately held molecular diagnostics company. Previously, Dr. Sheinerman was a Managing Director of Healthcare Investment Banking at Rodman & Renshaw. Prior to joining banking, Dr. Sheinerman worked at The Arcus Group, an oncology focused boutique consulting firm. From June 2020 to April 2023, Dr. Sheinerman served as the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008-2009, Dr. Sheinerman chaired the Board Executive Committee of Xenomics (now Cardiff Oncology; NASDAQ: CRDF ). From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University, and from 2015 through 2018 she served as the co-chair of the Alzheimer’s Association Business Consortium. Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer’s Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY.
